Two study teams have had recent national and global patient recruitment success.
The Surgical research team recruited the first UK patient to the European Aortic Data Collection project on 7 June – within one day of being open to recruitment.
This is a European commercial vascular study designed to collect patient data on Cook’s custom-made endovascular grafts. The grafts treat aortic and aorto-iliac related diseases such as aneurysm and dissection under real-world conditions.
Also, the Renal research team are the highest recruiting site in the UK, and the joint second highest recruiting site globally, for the FINE-ONE study. This study evaluates the efficacy and safety of a drug which could delay the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes. The team has currently recruited four patients from a target of six (as of 10 June).
Jake Harley, NBT Commercial Trials Manager, said: “One of the most important things commercial sponsors are looking for from sites is the ability to recruit to time and target. That not only means recruiting the number of patients we predicted, but also demonstrating that when we are given the green light to recruit from the sponsor, our delivery teams are ready to start work and they can identify and recruit the first patient as quickly as possible.
Our teams have demonstrated robust local feasibility and set-up procedures which means sponsors are more likely to return with future study opportunities.”